Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability...

Full description

Bibliographic Details
Main Authors: Wout Devlies, Markus Eckstein, Alessia Cimadamore, Gaëtan Devos, Lisa Moris, Thomas Van den Broeck, Rodolfo Montironi, Steven Joniau, Frank Claessens, Thomas Gevaert
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cells
Subjects:
prostate cancer
biomarker
targeted therapies
histology
mCRPC
androgen receptor
Online Access:https://www.mdpi.com/2073-4409/9/11/2494
id doaj-6c3d8988567c470ebe95a3809bd25958
record_format Article
spelling doaj-6c3d8988567c470ebe95a3809bd259582020-11-25T04:09:46ZengMDPI AGCells2073-44092020-11-0192494249410.3390/cells9112494Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate CancerWout Devlies0Markus Eckstein1Alessia Cimadamore2Gaëtan Devos3Lisa Moris4Thomas Van den Broeck5Rodolfo Montironi6Steven Joniau7Frank Claessens8Thomas Gevaert9Department of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, 91054 Erlangen, GermanySection of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, ItalyDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumSection of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, 60121 Ancona, ItalyDepartment of Urology, University Hospitals Leuven, 3000 Leuven, BelgiumLaboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, BelgiumDepartment of Pathology, University Hospitals Leuven, 3000 Leuven, BelgiumThe development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.https://www.mdpi.com/2073-4409/9/11/2494prostate cancerbiomarkertargeted therapieshistologymCRPCandrogen receptor
collection DOAJ
language English
format Article
sources DOAJ
author Wout Devlies
Markus Eckstein
Alessia Cimadamore
Gaëtan Devos
Lisa Moris
Thomas Van den Broeck
Rodolfo Montironi
Steven Joniau
Frank Claessens
Thomas Gevaert
spellingShingle Wout Devlies
Markus Eckstein
Alessia Cimadamore
Gaëtan Devos
Lisa Moris
Thomas Van den Broeck
Rodolfo Montironi
Steven Joniau
Frank Claessens
Thomas Gevaert
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Cells
prostate cancer
biomarker
targeted therapies
histology
mCRPC
androgen receptor
author_facet Wout Devlies
Markus Eckstein
Alessia Cimadamore
Gaëtan Devos
Lisa Moris
Thomas Van den Broeck
Rodolfo Montironi
Steven Joniau
Frank Claessens
Thomas Gevaert
author_sort Wout Devlies
title Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
title_short Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
title_full Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
title_fullStr Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
title_full_unstemmed Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
title_sort clinical actionability of the genomic landscape of metastatic castration resistant prostate cancer
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2020-11-01
description The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
topic prostate cancer
biomarker
targeted therapies
histology
mCRPC
androgen receptor
url https://www.mdpi.com/2073-4409/9/11/2494
work_keys_str_mv AT woutdevlies clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT markuseckstein clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT alessiacimadamore clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT gaetandevos clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT lisamoris clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT thomasvandenbroeck clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT rodolfomontironi clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT stevenjoniau clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT frankclaessens clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
AT thomasgevaert clinicalactionabilityofthegenomiclandscapeofmetastaticcastrationresistantprostatecancer
_version_ 1724421861464342528

Similar Items